Research Study

A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Principal Investigator 
Nazira Chatur

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT03383146
Status 
Recruiting
Study Start/End 
Feb 14, 2019 to Apr 18, 2022
Locations 
Diamond Health Care Centre
Name/Title 
Jo-Ann Ford, Clinical Research Coordinator
Phone 
604-875-5705
Email Address 
jo-ann.ford@vch.ca
Purpose of Study 

The purpose of this study is to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.